---
schema_version: "secwatch.filing_event.v1"
accession: "0001694665-23-000034"
form_type: "8-K"
ticker: null
cik: "0001694665"
company_name: "Evelo Biosciences, Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:08:31.773953+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evelo Biosciences receives Nasdaq deficiency notices for MVLS and MVPHS below thresholds

## Summary
- MVLS below $50M for 30 consecutive business days; compliance period ends Oct 23, 2023.
- MVPHS below $15M for 30 consecutive business days; compliance period ends Oct 25, 2023.
- Stock continues trading under EVLO while company monitors compliance and evaluates options.
- Company may appeal delisting or apply to transfer to Nasdaq Capital Market if non-compliant.

## SEC filing metadata
- accession: 0001694665-23-000034
- form_type: 8-K
- cik: 0001694665
- company_name: Evelo Biosciences, Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1694665/000169466523000034/0001694665-23-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1694665/000169466523000034/evlo-20230425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001694665-23-000034
- JSON: https://secwatch.observer/filing/0001694665-23-000034.json
- Plain text: https://secwatch.observer/filing/0001694665-23-000034.txt

## Key facts
- Listing & Compliance Notices
  Evelo Biosciences, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A)
  source text: April 25, 2023, Evelo Biosciences, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the Minimum Value of Listed Securities, as defined by Nasdaq (“MVLS”), of the Company’s common stock, par value $0.001 per share (the “Common Stock”), has been below the minimum $50 million requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(b)(2)(A) (the “Minimum Market Value of Listed Securities Requirement”). On April
  evidence_url: https://www.sec.gov/Archives/edgar/data/1694665/000169466523000034/0001694665-23-000034-index.htm
- Listing & Compliance Notices
  Evelo Biosciences, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(C)
  source text: April 28, 2023, the Company received a letter from the Listing Qualifications Department of Nasdaq notifying the Company that, for the last 30 consecutive business days, the Company’s minimum Market Value of Publicly Held Shares, as defined by Nasdaq (“MVPHS”), of the Company’s Common Stock has been below the minimum $15 million requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum Market Value of Publicly Held Shares Requirement”). These letters have no immediate effect on the listing of the Common Stock on the Nasdaq Global
  evidence_url: https://www.sec.gov/Archives/edgar/data/1694665/000169466523000034/0001694665-23-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.